Perceptive Advisors LLC boosted its holdings in shares of Global Blood Therapeutics Inc (NASDAQ:GBT) by 14.7% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,889,066 shares of the company’s stock after purchasing an additional 625,000 shares during the period. Global Blood Therapeutics comprises 6.4% of Perceptive Advisors LLC’s portfolio, making the stock its 3rd biggest holding. Perceptive Advisors LLC owned about 10.63% of Global Blood Therapeutics worth $192,384,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also made changes to their positions in the company. Point72 Asset Management L.P. raised its stake in shares of Global Blood Therapeutics by 189.5% in the third quarter. Point72 Asset Management L.P. now owns 2,022,700 shares of the company’s stock valued at $62,805,000 after acquiring an additional 1,323,934 shares during the last quarter. RTW Investments LP raised its stake in shares of Global Blood Therapeutics by 2,186.9% in the fourth quarter. RTW Investments LP now owns 601,683 shares of the company’s stock valued at $23,676,000 after acquiring an additional 575,373 shares during the last quarter. Citadel Advisors LLC raised its stake in shares of Global Blood Therapeutics by 161.7% in the fourth quarter. Citadel Advisors LLC now owns 716,611 shares of the company’s stock valued at $28,199,000 after acquiring an additional 442,828 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Global Blood Therapeutics by 43.8% in the third quarter. Janus Henderson Group PLC now owns 1,415,558 shares of the company’s stock valued at $43,953,000 after acquiring an additional 431,325 shares during the last quarter. Finally, Farallon Capital Management LLC bought a new position in shares of Global Blood Therapeutics in the fourth quarter valued at approximately $13,379,000. Hedge funds and other institutional investors own 92.06% of the company’s stock.
In related news, major shareholder Perceptive Advisors Llc purchased 175,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 19th. The shares were acquired at an average price of $38.00 per share, for a total transaction of $6,650,000.00. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Peter Radovich sold 15,000 shares of the company’s stock in a transaction dated Wednesday, January 10th. The shares were sold at an average price of $50.00, for a total transaction of $750,000.00. Following the completion of the transaction, the insider now owns 17,684 shares in the company, valued at approximately $884,200. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 54,911 shares of company stock worth $3,059,552. 5.30% of the stock is owned by insiders.
Shares of Global Blood Therapeutics Inc (NASDAQ:GBT) opened at $57.15 on Monday. The company has a market cap of $2,689.70, a price-to-earnings ratio of -20.78 and a beta of 4.31. Global Blood Therapeutics Inc has a 52-week low of $24.02 and a 52-week high of $68.05.
Global Blood Therapeutics (NASDAQ:GBT) last issued its earnings results on Tuesday, February 27th. The company reported ($0.94) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.72) by ($0.22). equities analysts predict that Global Blood Therapeutics Inc will post -3.61 EPS for the current year.
About Global Blood Therapeutics
Global Blood Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing therapeutics to treat blood-based disorders. The Company is developing its initial product candidate, GBT440, as an oral, once-daily therapy for sickle cell disease (SCD).
Receive News & Ratings for Global Blood Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Global Blood Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.